Zhang Yanzhi, Wang Peng, Shi Mumu, Sasano Hironobu, Chan Monica S M, Dai Jiali, Guo Lunshu, Liu Ming, Wang Xiaoyan, Ma Ying, Wang Lin
*Yanzhi Zhang and Peng Wang equally contributed to this work.
Int J Biol Markers. 2014 Mar 24;29(1):e1-7. doi: 10.5301/jbm.5000078.
Disparities of biomarkers' expression in breast cancer across different races and ethnicities have been well documented. Proline, glutamic acid, and leucine-rich protein 1 (PELP1), a novel ER coregulator, has been considered as a promising biomarker of breast cancer prognosis; however, the pattern of PELP1 expression in Chinese women with breast cancer has never been investigated. This study aims to provide useful reference on possible racial or ethnic differences of PELP1 expression in breast cancer by exploring the pattern of PELP1 expression in Chinese women with primary breast cancer.
The expression of PELP1 in primary breast cancer samples from 130 Chinese female patients was detected by immunohistochemistry and correlated to other clinicopathological parameters; for comparison, the expression of PELP1 in 26 benign breast fibroadenomas was also examined.
The overall value of the PELP1 H-score in breast cancer was significantly higher than that in breast fibroadenoma (p<0.001). In our breast cancer patients, the ER/HER-2-positive group had significantly higher PELP1 H-scores than their negative counterparts (p=0.003 for ER and p=0.022 for HER-2); the Ki-67-high group also showed significantly higher PELP1 H-scores than the Ki-67-low group (p=0.008). No significant association between PELP1 H-scores and other clinicopathological parameters was found. Finally, the PELP1 H-score in breast cancers of the luminal B subtype was significantly higher than that in the triple negative subtype (p=0.002).
Overexpression of PELP1 in Chinese women with primary breast cancer appears to be associated with biomarkers of poor outcome; these results are similar to other reports based on Western populations.
乳腺癌生物标志物表达在不同种族和民族之间的差异已有充分记录。脯氨酸、谷氨酸和亮氨酸丰富蛋白1（PELP1）是一种新型雌激素受体共调节因子，被认为是乳腺癌预后的一个有前景的生物标志物；然而，中国乳腺癌女性患者中PELP1的表达模式从未被研究过。本研究旨在通过探索中国原发性乳腺癌女性患者中PELP1的表达模式，为乳腺癌中PELP1表达可能存在的种族或民族差异提供有用的参考。
采用免疫组织化学法检测130例中国女性原发性乳腺癌患者样本中PELP1的表达，并将其与其他临床病理参数相关联；为作比较，还检测了26例乳腺良性纤维腺瘤中PELP1的表达。
乳腺癌中PELP1的H评分总体值显著高于乳腺纤维腺瘤（p<0.001）。在我们的乳腺癌患者中，雌激素受体/人表皮生长因子受体2（ER/HER-2）阳性组的PELP1 H评分显著高于阴性组（ER为p=0.003，HER-2为p=0.022）；Ki-67高表达组的PELP1 H评分也显著高于Ki-67低表达组（p=0.008）。未发现PELP1 H评分与其他临床病理参数之间存在显著关联。最后，管腔B亚型乳腺癌中的PELP1 H评分显著高于三阴性亚型（p=0.002）。
中国原发性乳腺癌女性患者中PELP1的过表达似乎与预后不良的生物标志物相关；这些结果与基于西方人群的其他报道相似。
